Tailor-Made vaccine aims to train immune system against cancer
NCT ID NCT07680582
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combination and see how well it triggers an immune response. Participants include those who have had surgery for their cancer or have advanced disease, and the trial will also look for early signs that the vaccine might help prevent the cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized cancer vaccine (ABO2109) and toripalimab (anti-PD-1 antibody)
What this could lead to
If successful, this could pave the way for a personalized vaccine that trains the immune system to fight residual cancer cells after surgery, potentially reducing recurrence risk.
What could go wrong
This is a very early (Phase 1) study with only 60 participants, so safety and effectiveness are not yet proven. The vaccine is personalized, making it complex and costly, and it may not work for all tumor types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- IBR854 Cell Therapy for Solid Tumors - NCT06001684
- SCB0020160 First-in-Human Safety Trial (NCT07682337)
- SI-B036 Bispecific Antibody Trial for Solid Tumo NCT07678970
- YZJ-5053 for Advanced Solid Tumors – Phase 1 Tri NCT06209385
- REDIRICT: High-Dose Re-Irradiation Study (NCT05301101)
- SHR-4685 for Solid Tumors Phase 1 Trial NCT07676903
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••